Company Overview and News

313
Avenir Global Fund Q1 '18 Commentary: Long Synchrony

2018-05-01 seekingalpha
The Avenir Global Fund - Class I units (the "Class I Fund") declined 1.3%, net of fees, during the March 2018 quarter. The retail class of the Avenir Global Fund ("Avenir Global Fund") also declined 1.3%, net of fees, for the quarter and has increased 11.4%, net of fees, since inception on 25 August 2017. The MSCI ACWI index (in AUD) returned 1.0% for the March 2018 quarter while the S&P 500 returned negative 0.
LOW TGLS BXG CRMLY PYPL WMT AMZN HCA GM.WS.A GM.WS.B GM.WS.C GM GE GEC C BBX SYF 0100 NXST DTG BABA GNE CRMLF GM.WSB DRTGF ADS

481
Mittleman Investment Management 1Q18 Commentary

2018-04-13 seekingalpha
Mittleman Investment Management, LLC's composite declined 11.3% net of fees in the first quarter of 2018, versus declines of 0.8% in the S&P 500 Total Return Index and 0.1% in the Russell 2000 Total Return Index. Longer-term results for our composite through 3/31/18 are presented below:
PM DB SGMS IGT RAD CRMLY VLRSY GAPFF AC BAC AMZN IRLTY CSCO PAA CCO IQV RGC MO AMC VRL VLRDF 0100 CKEC BRK.A BABA ACDVF PRAH VLRDY CRMLF ADS

0
Clear Media Ltd. ADR 2017 Q4 - Results - Earnings Call Slides

2018-04-09 seekingalpha
The following slide deck was published by Clear Media Ltd. ADR in conjunction with their 2017 Q4 earnings call.
CRMLY CRMLF 0100

16
Clear Channel Outdoors: iHeartMedia Bankruptcy Implications

2018-03-21 seekingalpha
iHeartMedia has used Clear Channel Outdoors, which it controls, as its own personal piggybank for years.
LSXMB BATRK FWONB LSXMA CRMLY BATRR 0100 FWONA SIRI FWONK BATRB LSXMK CRMLF CCO BATRA

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...